Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Cardiovasc Drugs Ther ; 35(3): 411-425, 2021 06.
Artículo en Inglés | MEDLINE | ID: mdl-32926272

RESUMEN

The recent emergence of the coronavirus disease 19 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in China is now a global health emergency. The transmission of SARS-CoV-2 is mainly via human-to-human contact. This virus is expected to be of zoonotic origin and has a high genome identity to that of bat derived SARS-like coronavirus. Various stringent measures have been implemented to lower person-to-person transmission of COVID-19. Particular observations and attempts have been made to reduce transmission in vulnerable populations, including older adults, children, and healthcare providers. This novel CoV enters the cells through the angiotensin-converting enzyme 2 (ACE2) receptor. There is a higher risk of COVID-19 infection among those with preexisting cardiovascular diseases (CVD), and it has been connected with various direct and indirect complications, including myocarditis, acute myocardial injury, venous thromboembolism, and arrhythmias. This article summarizes the various cardiovascular complications and mechanisms responsible for the same with COVID-19 infection. For the benefit of the scientific community and public, the effect of COVID-19 on major vital organs such as the kidneys, liver, and intestines has been briefly discussed. In this review, we also discuss drugs in different stages of clinical trials and their associated complications, as well as the details of vaccines in various stages of development.


Asunto(s)
COVID-19/complicaciones , Enfermedades Cardiovasculares/complicaciones , SARS-CoV-2 , Enzima Convertidora de Angiotensina 2/fisiología , Antivirales/efectos adversos , COVID-19/inmunología , Síndrome de Liberación de Citoquinas/etiología , Células Endoteliales/fisiología , Humanos , Hipertensión/complicaciones , Inmunidad Innata , Infarto del Miocardio/complicaciones , Caracteres Sexuales , Trombofilia/etiología , Tratamiento Farmacológico de COVID-19
2.
Cardiol Res ; 8(4): 176-178, 2017 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-28868105

RESUMEN

Superior vena cava (SVC) aneurysms are rare mediastinal vascular lesions. We report a case of a 42-year-old female, who presented to the outpatient department with features suggestive of lower respiratory tract infection. Chest X-ray showed abnormal contour and widening of right border of mediastinum. Computed tomography (CT) thorax revealed fusiform aneurysmal ectasia of SVC measuring 4.5 × 5.5 × 8.9 cm without internal thrombosis or dissecting flap. Management options include observation with follow-up and in some cases anticoagulation and surgical excision may be considered. The general consensus is that fusiform variety can be managed conservatively in view of the low risk of complications. The saccular aneurysms may need to be managed with anticoagulation therapy or surgically in view of the possible risk for thrombus formation and pulmonary embolism. Since in our case it was an asymptomatic primary fusiform SVC aneurysm, patient was advised for conservative management and follow-up.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA